关于停药的相关内容

摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。
. e: {' a, j8 K6 m    关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。

5 V* `! H2 l  k5 `; f$ F作者：来自澳大利亚
' V" m6 k5 w* w* V0 k来源：Haematologica. 2011.8.9.
Dear Group,

# M$ f8 p( r! |+ f' d& j( N8 oSome of you are on Dasatinib (Sprycel) and we wish to give news on all CML
* K/ O& E2 J# R) l! G. H8 ltherapies. Here is a report from Australia on 3 patients who went off Sprycel
2 z+ v( W' Y2 b1 xafter stable molecular response (PCRU). 1 patient relapsed but 2/3 patients
remain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel
does spike up the immune system so I hope more reports come out on this issue.
3 k: I# Y; `( W6 P% ~* c% m
" N# [, k( T' v8 d9 W7 _" d7 WThe remarkable news about Sprycel cessation is that all 3 patients had failed
! {# i& y# P8 }5 A  kGleevec and Sprycel was their second TKI so they had resistant disease. This is
different from the stopping Gleevec trial in France which only targets patients
  }2 @  g, K. y4 Y4 Mwho have done well on Gleevec.
3 {" g1 H: }% f
3 n+ W7 q% h$ C* G( m' W0 dHopefully, the doctors will report on a larger study and long-term to see if the
# w& \; z; R  D# |% N7 tresponse off Sprycel is sustained.

Best Wishes,
6 r0 g0 ]/ L  O' _- `& j" HAnjana

& d6 R# c! r) T/ G  C6 d

1 N. y& G" N$ d$ E" z& ^Haematologica. 2011 Aug 9. [Epub ahead of print]
Durable complete molecular remission of chronic myeloid leukemia following
dasatinib cessation, despite adverse disease features.
Ross DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.
Source
* q# c# V) Q- F, MAdelaide, Australia;
; j6 C, z2 a9 O- d& o! j$ s" y) P) \: p
Abstract
Patients with chronic myeloid leukemia, treated with imatinib, who have a
durable complete molecular response might remain in CMR after stopping
treatment. Previous reports of patients stopping treatment in complete molecular
6 i2 o; c: Y+ l* Mresponse have included only patients with a good response to imatinib. We
6 ]! K) O+ P) R: Y4 m3 w1 x+ Adescribe three patients with stable complete molecular response on dasatinib
6 B: S1 H8 ^% o9 n; M2 }5 Ptreatment following imatinib failure. Two of the three patients remain in
complete molecular response more than 12 months after stopping dasatinib. In
$ i0 {5 P' D) Z# |these two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to
) }0 @+ \* S& g% ~) @% xshow that the leukemic clone remains detectable, as we have previously shown in
imatinib-treated patients. Dasatinib-associated immunological phenomena, such as
the emergence of clonal T cell populations, were observed both in one patient
who relapsed and in one patient in remission. Our results suggest that the
1 S, D7 C$ I2 V1 Kcharacteristics of complete molecular response on dasatinib treatment may be
similar to that achieved with imatinib, at least in patients with adverse
9 o, W) ]8 _6 F$ {" C: kdisease features.
, [" }  O( L' K6 K! H" {+ \

摘要：（STIM试验为法国的格列卫停药试验。）这个研究中，患者先是取得了CMR（融合基因转阴），然后停用格列卫，而后复发。15名复发患者在重新服药后又一次取得了CMR，他们同意再次停药。
, U. r! B" B% I4 ^    第一次CMR持续时间为31个月，然后患者停药，复发的中位时间为2.6个月，然后重新服用格列卫，中位时间5.3个月之后取得第二次CMR。保持第二次CMR中位时间19个月之后，患者同意再次停药，这次，15名患者中有5名在停药随访中位时间24个月后仍然保持了CMR，而10名患者在停药中位时间2月后第二次复发。
- \( d3 a/ g$ n6 k% V. {2 |    请注意，这些患者都是在第一次CMR后停药然后又复发的患者。
! a- O5 H! D7 }* e& z0 L* s
作者：来自法国STIM试验
% {8 ~, `+ L7 v; u来源：EHA 2011.6.会议摘要

很不错的文章，看来马老师家有考虑停药的想法了啊！祝福！

期盼易或特也能停药，但现在觉得是一个梦想！

这个非常有意义的研究。能吃下来停会再吃，再停，那是天大的好事